Mostrar el registro sencillo del ítem
dc.contributor.author | Malapelle, Umberto | es_ES |
dc.contributor.author | Sirera Pérez, Rafael | es_ES |
dc.contributor.author | Jantus-Lewintre, Eloisa | es_ES |
dc.contributor.author | Reclusa, P. | es_ES |
dc.contributor.author | Calabuig-Farinas, S. | es_ES |
dc.contributor.author | Blasco, Ana | es_ES |
dc.contributor.author | Pisapia, P. | es_ES |
dc.contributor.author | Rolfo, C. | es_ES |
dc.contributor.author | Camps, Carlos | es_ES |
dc.date.accessioned | 2020-07-14T03:31:14Z | |
dc.date.available | 2020-07-14T03:31:14Z | |
dc.date.issued | 2017 | es_ES |
dc.identifier.issn | 1473-7159 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10251/147918 | |
dc.description.abstract | [EN] Introduction: The discovery of driver mutations in non-small cell lung cancer (NSCLC) has led to the development of genome-based personalized medicine. Fifteen to 20% of adenocarcinomas harbor an epidermal growth factor receptor (EGFR) activating mutation associated with responses to EGFR tyrosine kinase inhibitors (TKIs). Individual laboratories' expertise and the availability of appropriate equipment are valuable assets in predictive molecular pathology, although the choice of methods should be determined by the nature of the samples to be tested and whether the detection of only well-characterized EGFR mutations or rather, of all detectable mutations, is required.Areas covered: The EGFR mutation testing landscape is manifold and includes both screening and targeted methods, each with their own pros and cons. Here we review one of these companion tests, the Roche cobas (R) EGFR mutation test v2, from a methodological point of view, also exploring its liquid-biopsy applications.Expert commentary: The Roche cobas (R) EGFR mutation test v2, based on real time RT-PCR, is a reliable option for testing EGFR mutations in clinical practice, either using tissue-derived DNA or plasma-derived cfDNA. This application will be valuable for laboratories with whose purpose is purely diagnostic and lacking high-throughput technologies. | es_ES |
dc.description.sponsorship | This work was partially supported by FEDER, CIBERONC, grant number [CB16/12/00350]. | es_ES |
dc.language | Inglés | es_ES |
dc.publisher | Taylor & Francis | es_ES |
dc.relation.ispartof | Expert Review of Molecular Diagnostics | es_ES |
dc.rights | Reserva de todos los derechos | es_ES |
dc.subject | EGFR | es_ES |
dc.subject | Cobas (R) | es_ES |
dc.subject | Liquid biopsy | es_ES |
dc.subject | Companion diagnostic | es_ES |
dc.subject | Mutation | es_ES |
dc.subject | Resistance | es_ES |
dc.subject | TKIs | es_ES |
dc.subject.classification | BIOLOGIA CELULAR | es_ES |
dc.title | Profile of the Roche cobas (R) EGFR mutation test for non-small cell lung cancer | es_ES |
dc.type | Artículo | es_ES |
dc.identifier.doi | 10.1080/14737159.2017.1288568 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//CB16%2F12%2F00350/ES/CANCER/ | es_ES |
dc.rights.accessRights | Cerrado | es_ES |
dc.contributor.affiliation | Universitat Politècnica de València. Departamento de Biotecnología - Departament de Biotecnologia | es_ES |
dc.description.bibliographicCitation | Malapelle, U.; Sirera Pérez, R.; Jantus-Lewintre, E.; Reclusa, P.; Calabuig-Farinas, S.; Blasco, A.; Pisapia, P.... (2017). Profile of the Roche cobas (R) EGFR mutation test for non-small cell lung cancer. Expert Review of Molecular Diagnostics. 17(3):209-215. https://doi.org/10.1080/14737159.2017.1288568 | es_ES |
dc.description.accrualMethod | S | es_ES |
dc.relation.publisherversion | https://doi.org/10.1080/14737159.2017.1288568 | es_ES |
dc.description.upvformatpinicio | 209 | es_ES |
dc.description.upvformatpfin | 215 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.description.volume | 17 | es_ES |
dc.description.issue | 3 | es_ES |
dc.identifier.pmid | 28129709 | es_ES |
dc.relation.pasarela | S\352272 | es_ES |
dc.contributor.funder | European Regional Development Fund | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad | es_ES |
dc.description.references | Ridge, C., McErlean, A., & Ginsberg, M. (2013). Epidemiology of Lung Cancer. Seminars in Interventional Radiology, 30(02), 093-098. doi:10.1055/s-0033-1342949 | es_ES |
dc.description.references | Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., … Fukuoka, M. (2009). Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine, 361(10), 947-957. doi:10.1056/nejmoa0810699 | es_ES |
dc.description.references | Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., … Haber, D. A. (2004). Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine, 350(21), 2129-2139. doi:10.1056/nejmoa040938 | es_ES |
dc.description.references | Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., … Sanchez, J. M. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology, 13(3), 239-246. doi:10.1016/s1470-2045(11)70393-x | es_ES |
dc.description.references | Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., … Sequist, L. V. (2015). Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet Oncology, 16(2), 141-151. doi:10.1016/s1470-2045(14)71173-8 | es_ES |
dc.description.references | Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., … Ranson, M. (2015). AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer. New England Journal of Medicine, 372(18), 1689-1699. doi:10.1056/nejmoa1411817 | es_ES |
dc.description.references | Pirker, R., Herth, F. J. F., Kerr, K. M., Filipits, M., Taron, M., Gandara, D., … Stahel, R. (2010). Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop. Journal of Thoracic Oncology, 5(10), 1706-1713. doi:10.1097/jto.0b013e3181f1c8de | es_ES |
dc.description.references | Malapelle, U., Russo, S., Pepe, F., Sgariglia, R., De Luca, C., Bellevicine, C., … Troncone, G. (2013). EGFR mutation detection by microfluidic technology: a validation study. Journal of Clinical Pathology, 66(11), 982-984. doi:10.1136/jclinpath-2013-201730 | es_ES |
dc.description.references | Malapelle, U., Bellevicine, C., De Luca, C., Salatiello, M., De Stefano, A., Rocco, D., … Troncone, G. (2013). EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. Cancer Cytopathology, 121(10), 552-560. doi:10.1002/cncy.21322 | es_ES |
dc.description.references | Giannini, R., Lupi, C., Sensi, E., Alì, G., Proietti, A., Boldrini, L., … Fontanini, G. (2016). EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. Oncology Reports, 36(2), 1166-1172. doi:10.3892/or.2016.4874 | es_ES |
dc.description.references | De Biase, D., Visani, M., Malapelle, U., Simonato, F., Cesari, V., Bellevicine, C., … Tallini, G. (2013). Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy). PLoS ONE, 8(12), e83607. doi:10.1371/journal.pone.0083607 | es_ES |
dc.description.references | Lozano, M. D., Labiano, T., Echeveste, J., Gurpide, A., Martín‐Algarra, S., Zhang, G., … Palma, J. F. (2014). Assessment of EGFR and KRAS mutation status from FNAs and core‐needle biopsies of non‐small cell lung cancer. Cancer Cytopathology, 123(4), 230-236. doi:10.1002/cncy.21513 | es_ES |
dc.description.references | Hantson, I., Dooms, C., Verbeken, E., Vandenberghe, P., Vliegen, L., Roskams, T., … Vansteenkiste, J. (2014). Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study. Translational Respiratory Medicine, 2(1). doi:10.1186/s40247-014-0009-0 | es_ES |
dc.description.references | Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013). Liquid biopsy: monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology, 10(8), 472-484. doi:10.1038/nrclinonc.2013.110 | es_ES |
dc.description.references | Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011). Cell-free nucleic acids as biomarkers in cancer patients. Nature Reviews Cancer, 11(6), 426-437. doi:10.1038/nrc3066 | es_ES |
dc.description.references | Sundaresan, T. K., Sequist, L. V., Heymach, J. V., Riely, G. J., Ja nne, P. A., Koch, W. H., … Haber, D. A. (2015). Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clinical Cancer Research, 22(5), 1103-1110. doi:10.1158/1078-0432.ccr-15-1031 | es_ES |
dc.description.references | Chia, P. L., Do, H., Morey, A., Mitchell, P., Dobrovic, A., & John, T. (2016). Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment. Lung Cancer, 98, 29-32. doi:10.1016/j.lungcan.2016.05.003 | es_ES |
dc.description.references | Alix-Panabières, C., & Pantel, K. (2013). Circulating Tumor Cells: Liquid Biopsy of Cancer. Clinical Chemistry, 59(1), 110-118. doi:10.1373/clinchem.2012.194258 | es_ES |
dc.description.references | Yao, Y., Liu, J., Li, L., Yuan, Y., Nan, K., Wu, X., … Jiang, Z. (2016). Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer. Oncotarget, 8(2), 2130-2140. doi:10.18632/oncotarget.12883 | es_ES |
dc.description.references | Camps, C., Jantus-Lewintre, E., Cabrera, A., Blasco, A., Sanmartín, E., Gallach, S., … Sirera, R. (2011). The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer, 72(3), 365-369. doi:10.1016/j.lungcan.2010.09.005 | es_ES |
dc.description.references | Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., … Rosenfeld, N. (2013). Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. New England Journal of Medicine, 368(13), 1199-1209. doi:10.1056/nejmoa1213261 | es_ES |
dc.description.references | Ankeny, J. S., Court, C. M., Hou, S., Li, Q., Song, M., Wu, D., … Tomlinson, J. S. (2016). Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. British Journal of Cancer, 114(12), 1367-1375. doi:10.1038/bjc.2016.121 | es_ES |
dc.description.references | Tan, C. R. C., Zhou, L., & El-Deiry, W. S. (2016). Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons. Current Colorectal Cancer Reports, 12(3), 151-161. doi:10.1007/s11888-016-0320-y | es_ES |
dc.description.references | Malapelle, U., Pisapia, P., Rocco, D., Smeraglio, R., di Spirito, M., Bellevicine, C., & Troncone, G. (2016). Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients. Translational Lung Cancer Research, 5(5), 505-510. doi:10.21037/tlcr.2016.10.08 | es_ES |
dc.description.references | Sirera, R., Bremnes, R. M., Cabrera, A., Jantus-Lewintre, E., Sanmartín, E., Blasco, A., … Camps, C. (2011). Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 6(2), 286-290. doi:10.1097/jto.0b013e31820189a5 | es_ES |
dc.description.references | Lianidou, E. S., Mavroudis, D., & Georgoulias, V. (2013). Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. British Journal of Cancer, 108(12), 2426-2432. doi:10.1038/bjc.2013.265 | es_ES |
dc.description.references | Diamandis, E. P., Pantel, K., Scher, H. I., Terstappen, L., & Lianidou, E. (2011). Circulating Cancer Cells and Their Clinical Applications. Clinical Chemistry, 57(11), 1478-1484. doi:10.1373/clinchem.2011.166678 | es_ES |
dc.description.references | Karachaliou, N., Mayo-de las Casas, C., Queralt, C., de Aguirre, I., Melloni, B., Cardenal, F., … Rosell, R. (2015). Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA Oncology, 1(2), 149. doi:10.1001/jamaoncol.2014.257 | es_ES |
dc.description.references | Pasquale, R., Fenizia, F., Esposito Abate, R., Sacco, A., Esposito, C., Forgione, L., … Normanno, N. (2015). Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. Pharmacogenomics, 16(10), 1135-1148. doi:10.2217/pgs.15.45 | es_ES |
dc.description.references | Thress, K. S., Brant, R., Carr, T. H., Dearden, S., Jenkins, S., Brown, H., … Barrett, J. C. (2015). EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer, 90(3), 509-515. doi:10.1016/j.lungcan.2015.10.004 | es_ES |
dc.description.references | Kimura, H., Ohira, T., Uchida, O., Matsubayashi, J., Shimizu, S., Nagao, T., … Nishio, K. (2014). Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer. Lung Cancer, 83(3), 329-333. doi:10.1016/j.lungcan.2013.12.012 | es_ES |
dc.description.references | Benlloch, S., Botero, M. L., Beltran-Alamillo, J., Mayo, C., Gimenez-Capitán, A., de Aguirre, I., … Taron, M. (2014). Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial. PLoS ONE, 9(2), e89518. doi:10.1371/journal.pone.0089518 | es_ES |
dc.description.references | Wu, Y.-L., Zhou, C., Liam, C.-K., Wu, G., Liu, X., Zhong, Z., … Zuo, Y. (2015). First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Annals of Oncology, 26(9), 1883-1889. doi:10.1093/annonc/mdv270 | es_ES |
dc.description.references | Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., … Cadranel, J. (2014). Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Annals of Oncology, 25(1), 126-131. doi:10.1093/annonc/mdt418 | es_ES |
dc.description.references | Yasuda, H., Kobayashi, S., & Costa, D. B. (2012). EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. The Lancet Oncology, 13(1), e23-e31. doi:10.1016/s1470-2045(11)70129-2 | es_ES |
dc.description.references | Oxnard, G. R., Thress, K. S., Alden, R. S., Lawrance, R., Paweletz, C. P., Cantarini, M., … Jänne, P. A. (2016). Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 34(28), 3375-3382. doi:10.1200/jco.2016.66.7162 | es_ES |
dc.description.references | Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., … Halmos, B. (2005). EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine, 352(8), 786-792. doi:10.1056/nejmoa044238 | es_ES |
dc.description.references | Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., … Pao, W. (2006). Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors. Clinical Cancer Research, 12(21), 6494-6501. doi:10.1158/1078-0432.ccr-06-1570 | es_ES |
dc.description.references | Costa, D. B., Schumer, S. T., Tenen, D. G., & Kobayashi, S. (2008). Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations. Journal of Clinical Oncology, 26(7), 1182-1184. doi:10.1200/jco.2007.14.9039 | es_ES |
dc.description.references | Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., … Oxnard, G. R. (2015). Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M. Nature Medicine, 21(6), 560-562. doi:10.1038/nm.3854 | es_ES |
dc.description.references | Bean, J., Riely, G. J., Balak, M., Marks, J. L., Ladanyi, M., Miller, V. A., & Pao, W. (2008). Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma. Clinical Cancer Research, 14(22), 7519-7525. doi:10.1158/1078-0432.ccr-08-0151 | es_ES |
dc.description.references | Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., … Janne, P. A. (2007). MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science, 316(5827), 1039-1043. doi:10.1126/science.1141478 | es_ES |